In vitro and in vivo inhibitory activity of 6-amino-2,4,5-trimethylpyridin-3-ols against inflammatory bowel disease
- Authors
- Banskota, Suhrid; Kang, Han-eol; Kim, Dong-Guk; Park, Sang Won; Jang, Hyeonjin; Karmacharya, Ujjwala; Jeong, Byeong-Seon; Kim, Jung-Ae; Nam, Tae-gyu
- Issue Date
- Oct-2016
- Publisher
- PERGAMON-ELSEVIER SCIENCE LTD
- Keywords
- Inflammatory bowel disease; TNF-alpha; 6-Amino-2,4,5-trimethylpyridin-3-ol; Cell adhesion; TNBS-induced colitis
- Citation
- BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, v.26, no.19, pp.4587 - 4591
- Indexed
- SCIE
SCOPUS
- Journal Title
- BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Volume
- 26
- Number
- 19
- Start Page
- 4587
- End Page
- 4591
- URI
- https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/12616
- DOI
- 10.1016/j.bmcl.2016.08.075
- ISSN
- 0960-894X
- Abstract
- Although the pathogenesis of inflammatory bowel disease (IBD) is complex, attachment and infiltration of leukocytes to gut epithelium induced by pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) represents the initial step of inflammation in IBD. Previously, we have reported that some 6-amino-2,4,5-trimethylpyridin-3-ols have significant levels of antiangiogenic activity via PI3K inhibition. Based on the reports that angiogenesis is involved in the aggravation of IBD and that PI3K is a potential target for IBD therapy, we investigated whether the scaffold has inhibitory activity against in vitro and in vivo models of colitis. Many analogues showed >80% inhibition against TNF-alpha-induced monocyte adhesion to colon epithelial cells at 1 mu M. Compound 8m showed IC50 = 0.19 mu M, which is about five orders of magnitude better than that of 5-aminosalicylic acid (5-ASA, IC50 = 18.1 mM), a positive control. In a rat model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis, orally administered 8m dramatically ameliorated TNBS-induced colon inflammation. It was demonstrated by a high level of suppression in myeloperoxidase (MPO), a surrogate marker of colitis, as well as almost perfect recovery of colon and body weights in a dose-dependent manner. Compared to sulfasalazine, a prodrug of 5-ASA, compound 8m showed >300-fold better efficacy in those parameters. Taken together, 6-amino-2,4,5-trimethylpyridin-3-ols can provide a novel platform for anti-IBD drug discovery. (C) 2016 Elsevier Ltd. All rights reserved.
- Files in This Item
-
Go to Link
- Appears in
Collections - COLLEGE OF PHARMACY > DEPARTMENT OF PHARMACY > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.